Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 8/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 8/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 8/20 | 1.00 |
| ▸ | ESR1 | P03372 | 9/20 | 0.88 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.88 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | MEN1 | O00255 | 3/20 | 0.88 |
| ▸ | TP53 | P04637 | 3/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.88 |
| ▸ | PGR | P06401 | 2/20 | 0.88 |
| ▸ | ESRRG | P62508 | 2/20 | 0.88 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.88 |
| ▸ | HTR6 | P50406 | 2/20 | 0.88 |
| ▸ | NPC1 | O15118 | 1/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.88 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.88 |
| ▸ | EGFR | P00533 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151532 | 1.00 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL7797461 | 1.00 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL7797462 | 1.00 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767718 | 0.94 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767725 | 0.94 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767709 | 0.94 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| Tamoxifen SCHEMBL60433 | 0.94 | ESR1 (0.95) | PDE1APDE1BPDE1CESR1ESR2 | |
| Tamoxifen SCHEMBL60434 | 0.94 | ESR1 (0.95) | PDE1APDE1BPDE1CESR1ESR2 | |
| Tamoxifen SCHEMBL17262111 | 0.94 | ESR1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| Tamoxifen SCHEMBL17262082 | 0.94 | ESR1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20100143473-A1 | COMBINATION TREATMENT WITH STRONTIUM FOR THE PROPHYLAXIS AND/OR TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS | OSTEOLOGIX A/S | 2010-06-10 | — | — | US | claimed |
| US-20090035315-A1 | Method of Improving Treatments in Rheumatic and Arthritic Diseases | OSTEOLOGIX A/S (DK) | 2009-02-05 | — | — | US | claimed |
| EP-1758653-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | Osteologix A/S (DK) | 2007-03-07 | — | — | EP | claimed |
| US-20060275503-A1 | Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions | NORDIC BONE A/S (DK) | 2006-12-07 | — | — | US | claimed |
| EP-1622630-A2 | STRONTIUM COMBINATIONS FOR THE PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS | Osteologix A/S (DK) | 2006-02-08 | — | — | EP | claimed |
| WO-2005123193-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123130-A2 | IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2004098618-A2 | STRONTIUM COMBINATIONS FOR PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS | OSTEOLOGIX A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| EP-1465619-A1 | SUPPRESSION OF CARTILAGE DEGRADATION VIA THE ESTROGEN RECEPTOR | Nordic Bioscience A/S (DK) | 2004-10-13 | — | — | EP | claimed |
| WO-2003063859-A1 | SUPPRESSION OF CARTILAGE DEGRADATION VIA THE ESTROGEN RECEPTOR | NORDIC BIOSCIENCE A/S (DK) | 2003-08-07 | — | — | WO | claimed |
| EP-1159963-A1 | Composition for and method of preventing or treating breast cancer | Protein Technologies International, Inc. (US) | 2001-12-05 | — | — | EP | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20010047033-A1 | Composition for and method of preventing or treating breast cancer | PROTEIN TECHNOLOGIES INTERNATIONAL, INC. | 2001-11-29 | — | — | US | disclosed |
| US-6300367-B1 | Composition for and method of preventing or treating breast cancer | PROTEIN TECHNOLOGIES INTERNATIONAL, INC. | 2001-10-09 | — | — | US | disclosed |
| US-6300367-B1 | Composition for and method of preventing or treating breast cancer | PROTEIN TECHNOLOGIES INTERNATIONAL, INC. | 2001-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | PDE1A 2872/4885PDE1B 2498/4885PDE1C 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.